Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Longqi Chen, Yongde Liao, Xiaolong Yan, Mingqiang Kang, Xinyu Mei, Lijie Tan, Junfeng Liu, Zhang Zhang, Lei Liang, Alysha Kadva, Hongjing Jiang
Institutions: Sichuan University, West China Hospital of Sichuan University, Wuhan Union Hospital, Huazhong University of Science and Technology, Tang Du Hospital, Air Force Medical University, Union Hospital, University of Science and Technology of China, Anhui Provincial Hospital, Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital, Hebei Medical University, Fourth Hospital of Hebei Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814539